Cosmetics & Personal Care | Monthly bulletin | June 2023
Upgrading your raw materials to meet new challenges of the cosmetics market
As the cosmetics market is changing fast, consumers are increasingly attracted to cosmetic products based on natural and organic raw materials. Furthermore, the emergence of new and therefore unknown raw materials is forcing raw material suppliers to be ever more vigilant in ensuring the safety and efficacy of their products.
Our teams of experts can support and advise you through the various stages of safety assessment and proof of efficacy for raw materials and ingredients, including:
- Regulatory & toxicology: raw material regulatory files, international compliance, support on pre-evaluation, safety evaluation, selecting necessary tests, raw material equivalence;
- Physico-chemical analyses (heavy metals, allergens, pesticides, PFAS, impurity, etc.);
- Microbiological testing (counting and identification)
- Ecotoxicity, biodegradability testing
- In vitro safety tests (skin irritation or mucous membrane, eye irritation, mutagenicity, genotoxicity, transcutaneous/percutaneous passage, endocrine disruptors), in vitro efficacy tests (models developed in-house to meet current claims);
- Ex vivo testing (models developed in-house to meet current claims);
- Cosmetogenomics to identify new markers of interest;
- Clinical testing;
- Sensory & emotion evaluation.
Eurofins Cosmetics & Personal Care can draw on a strong network of laboratories to ensure that your raw materials are safe for end-users, and will enable you to make accurate claims in line with current trends on the market, such as skin regeneration, anti-aging, skin longevity, high sensoriality, and more.
Ensure the sustainability of your cosmetic products
In recent years, consumers have become more conscientious and have a greater understanding and sense of responsibility when it comes to purchasing products which not only work and are good for their skin but are also ethical and environmentally friendly. This impacts several product categories and has inspired scientific breakthroughs and innovation.
Brands have to face new regulations and sustainability challenges, which entails new marketing claims. To make this possible, the Eurofins Cosmetics & Personal Care network of companies supports customers to work in a more sustainable way.
- Environmental impact: ecotoxicity & biodegradability testing, compostability testing, microplastics testing, recycled packaging, product life cycle analysis, carbon footprint, authenticity and traceability of raw materials, wastewater testing, water saving protocols and rinsability testing, PFAS, nanoparticules, microparticles, etc.
- Refillable solution: procedures for workers in shops and training, cleaning protocols, reusable packaging testing, “mystery” client audits and quality audits, quality control in shops
- Vegan offer: toxicology and regulatory assessment, animal DNA analysis, on-site audit, declarations of conformity / labelling
Follow the emerging trends of the global aesthetic industry
The global aesthetic industry is experiencing strong growth and is predicted to grow even further, as interest is increasing in new approaches to aesthetic dermatology. Emerging trends include new scientifically based cosmeceutical skin care products, invasive and non-invasive, physical, chemical and pharmacological treatment options, and holistic solutions that combine various methods and treatments.
Regulatory bodies all over the world have begun to implement new regulatory framework for a clearer definition and evaluation of safety and efficacy parameters, at the same time aiming to fight malpractice and the uncontrolled use of aesthetic procedures. This has significantly increased the need for clinical trials in this field.
Eurofins Cosmetics & Personal Care has strong experience in the management of aesthetic studies with medical devices, as well as with injectables, laser treatments, and more. With our established network of dermatological experts and key thought leaders in the aesthetic field, we provide expertise in conducting Phase I to IV studies for pharmaceuticals, as well as investigations within the scope of conformity assessments and post-market clinical follow-ups (EU MDR) for medical devices.
